Search research articles
Contact Us
Filters
Showing results (41-50 of 49) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 49 results.
Cancer Discovery
|
June 18, 2025
Tumor-associated NK Cells Regulate Distinct CD8+ T-cell Differentiation Program in Cancer and Contribute to Resistance against Immune Checkpoint Blockers
No-Joon Song, Juan Xie, Kyeong Joo Jung, et al.
Nature
|
October 1, 2025
Proteotoxic stress response drives T cell exhaustion and immune evasion
Yi Wang, Anjun Ma, No-Joon Song, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 31, 2021
TREATMENT WITH SOLUBLE CD24 ATTENUATES COVID-19-ASSOCIATED SYSTEMIC IMMUNOPATHOLOGY
No-Joon Song, Carter Allen, Anna E Vilgelm, et al.
Nature Immunology
|
March 28, 2026
ZFP148 is a transcriptional repressor of cytolytic effector CD8<sup>+</sup> T cell differentiation
Tong Xiao, Xingyu Chen, No-Joon Song, et al.
Journal of Hematology & Oncology
|
January 11, 2022
Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology
No-Joon Song, Carter Allen, Anna E Vilgelm, et al.
Research Square
|
February 23, 2026
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22
Sumithira Vasu, Nathan Denlinger, No-Joon Song, et al.
JCI Insight
|
February 7, 2023
Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapy
Joseph H Azar, John P Evans, Madison H Sikorski, et al.
Blood Advances
|
April 12, 2024
Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma
Nathan Denlinger, No-Joon Song, Xiaoli Zhang, et al.
Blood Cancer Discovery
|
July 14, 2026
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22
Sumithira Vasu, Nathan Denlinger, No-Joon Song, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 49) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 49 results.
Cancer Discovery
|
June 18, 2025
Tumor-associated NK Cells Regulate Distinct CD8+ T-cell Differentiation Program in Cancer and Contribute to Resistance against Immune Checkpoint Blockers
No-Joon Song, Juan Xie, Kyeong Joo Jung, et al.
Nature
|
October 1, 2025
Proteotoxic stress response drives T cell exhaustion and immune evasion
Yi Wang, Anjun Ma, No-Joon Song, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 31, 2021
TREATMENT WITH SOLUBLE CD24 ATTENUATES COVID-19-ASSOCIATED SYSTEMIC IMMUNOPATHOLOGY
No-Joon Song, Carter Allen, Anna E Vilgelm, et al.
Nature Immunology
|
March 28, 2026
ZFP148 is a transcriptional repressor of cytolytic effector CD8<sup>+</sup> T cell differentiation
Tong Xiao, Xingyu Chen, No-Joon Song, et al.
Journal of Hematology & Oncology
|
January 11, 2022
Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology
No-Joon Song, Carter Allen, Anna E Vilgelm, et al.
Research Square
|
February 23, 2026
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22
Sumithira Vasu, Nathan Denlinger, No-Joon Song, et al.
JCI Insight
|
February 7, 2023
Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapy
Joseph H Azar, John P Evans, Madison H Sikorski, et al.
Blood Advances
|
April 12, 2024
Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma
Nathan Denlinger, No-Joon Song, Xiaoli Zhang, et al.
Blood Cancer Discovery
|
July 14, 2026
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22
Sumithira Vasu, Nathan Denlinger, No-Joon Song, et al.
Page
of 5